# Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients

> **NCT00168181** · PHASE3 · COMPLETED · sponsor: **Alberta Health services** · enrollment: 220 (estimated)

## Conditions studied

- Cancer
- Head and Neck Cancer

## Interventions

- **PROCEDURE:** Submandibular gland Transfer
- **DRUG:** Salagen

## Key facts

- **NCT ID:** NCT00168181
- **Lead sponsor:** Alberta Health services
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** —
- **Final completion:** 2008-04
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2011-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168181, "Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00168181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*